An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States with ...

Italy: Patients with prostate cancer receiving maximal androgen blockade therapy face a significantly higher risk of bone ...

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival ...

Multimodal treatment including radical prostatectomy might lead to improved survival in patients with oligometastatic prostate cancer treated with ADT. Men with oligometastatic prostate cancer (OmPCa) ...

In North American studies, heart failure risk appeared to be lower among patients receiving ADT than it was for the overall analysis, whereas the risk with ADT across Asian studies was higher. The use ...